Blood Transcriptomes of Anti-SARS-CoV-2 Antibody-Positive Healthy Individuals Who Experienced Asymptomatic Versus Clinical Infection

The reasons behind the clinical variability of SARS-CoV-2 infection, ranging from asymptomatic infection to lethal disease, are still unclear. We performed genome-wide transcriptional whole-blood RNA sequencing, bioinformatics analysis and PCR validation to test the hypothesis that immune response-r...

Full description

Bibliographic Details
Main Authors: Petros P. Sfikakis, Kleio-Maria Verrou, Giannis Ampatziadis-Michailidis, Ourania Tsitsilonis, Dimitrios Paraskevis, Efstathios Kastritis, Evi Lianidou, Paraskevi Moutsatsou, Evangelos Terpos, Ioannis Trougakos, Vasiliki Chini, Menelaos Manoloukos, Panagiotis Moulos, Georgios A. Pavlopoulos, George Kollias, Pantelis Hatzis, Meletios A. Dimopoulos
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-10-01
Series:Frontiers in Immunology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2021.746203/full
id doaj-5544ae135ad64856b321e886966e1db2
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Petros P. Sfikakis
Petros P. Sfikakis
Kleio-Maria Verrou
Kleio-Maria Verrou
Giannis Ampatziadis-Michailidis
Ourania Tsitsilonis
Dimitrios Paraskevis
Efstathios Kastritis
Evi Lianidou
Paraskevi Moutsatsou
Evangelos Terpos
Ioannis Trougakos
Vasiliki Chini
Menelaos Manoloukos
Panagiotis Moulos
Panagiotis Moulos
Georgios A. Pavlopoulos
Georgios A. Pavlopoulos
George Kollias
George Kollias
George Kollias
Pantelis Hatzis
Pantelis Hatzis
Meletios A. Dimopoulos
Meletios A. Dimopoulos
spellingShingle Petros P. Sfikakis
Petros P. Sfikakis
Kleio-Maria Verrou
Kleio-Maria Verrou
Giannis Ampatziadis-Michailidis
Ourania Tsitsilonis
Dimitrios Paraskevis
Efstathios Kastritis
Evi Lianidou
Paraskevi Moutsatsou
Evangelos Terpos
Ioannis Trougakos
Vasiliki Chini
Menelaos Manoloukos
Panagiotis Moulos
Panagiotis Moulos
Georgios A. Pavlopoulos
Georgios A. Pavlopoulos
George Kollias
George Kollias
George Kollias
Pantelis Hatzis
Pantelis Hatzis
Meletios A. Dimopoulos
Meletios A. Dimopoulos
Blood Transcriptomes of Anti-SARS-CoV-2 Antibody-Positive Healthy Individuals Who Experienced Asymptomatic Versus Clinical Infection
Frontiers in Immunology
innate immunity
anti-SARS-CoV2 antibody
asympomatic
RNAseq
whole-blood
author_facet Petros P. Sfikakis
Petros P. Sfikakis
Kleio-Maria Verrou
Kleio-Maria Verrou
Giannis Ampatziadis-Michailidis
Ourania Tsitsilonis
Dimitrios Paraskevis
Efstathios Kastritis
Evi Lianidou
Paraskevi Moutsatsou
Evangelos Terpos
Ioannis Trougakos
Vasiliki Chini
Menelaos Manoloukos
Panagiotis Moulos
Panagiotis Moulos
Georgios A. Pavlopoulos
Georgios A. Pavlopoulos
George Kollias
George Kollias
George Kollias
Pantelis Hatzis
Pantelis Hatzis
Meletios A. Dimopoulos
Meletios A. Dimopoulos
author_sort Petros P. Sfikakis
title Blood Transcriptomes of Anti-SARS-CoV-2 Antibody-Positive Healthy Individuals Who Experienced Asymptomatic Versus Clinical Infection
title_short Blood Transcriptomes of Anti-SARS-CoV-2 Antibody-Positive Healthy Individuals Who Experienced Asymptomatic Versus Clinical Infection
title_full Blood Transcriptomes of Anti-SARS-CoV-2 Antibody-Positive Healthy Individuals Who Experienced Asymptomatic Versus Clinical Infection
title_fullStr Blood Transcriptomes of Anti-SARS-CoV-2 Antibody-Positive Healthy Individuals Who Experienced Asymptomatic Versus Clinical Infection
title_full_unstemmed Blood Transcriptomes of Anti-SARS-CoV-2 Antibody-Positive Healthy Individuals Who Experienced Asymptomatic Versus Clinical Infection
title_sort blood transcriptomes of anti-sars-cov-2 antibody-positive healthy individuals who experienced asymptomatic versus clinical infection
publisher Frontiers Media S.A.
series Frontiers in Immunology
issn 1664-3224
publishDate 2021-10-01
description The reasons behind the clinical variability of SARS-CoV-2 infection, ranging from asymptomatic infection to lethal disease, are still unclear. We performed genome-wide transcriptional whole-blood RNA sequencing, bioinformatics analysis and PCR validation to test the hypothesis that immune response-related gene signatures reflecting baseline may differ between healthy individuals, with an equally robust antibody response, who experienced an entirely asymptomatic (n=17) versus clinical SARS-CoV-2 infection (n=15) in the past months (mean of 14 weeks). Among 12.789 protein-coding genes analysed, we identified six and nine genes with significantly decreased or increased expression, respectively, in those with prior asymptomatic infection relatively to those with clinical infection. All six genes with decreased expression (IFIT3, IFI44L, RSAD2, FOLR3, PI3, ALOX15), are involved in innate immune response while the first two are interferon-induced proteins. Among genes with increased expression six are involved in immune response (GZMH, CLEC1B, CLEC12A), viral mRNA translation (GCAT), energy metabolism (CACNA2D2) and oxidative stress response (ENC1). Notably, 8/15 differentially expressed genes are regulated by interferons. Our results suggest that subtle differences at baseline expression of innate immunity-related genes may be associated with an asymptomatic disease course in SARS-CoV-2 infection. Whether a certain gene signature predicts, or not, those who will develop a more efficient immune response upon exposure to SARS-CoV-2, with implications for prioritization for vaccination, warrant further study.
topic innate immunity
anti-SARS-CoV2 antibody
asympomatic
RNAseq
whole-blood
url https://www.frontiersin.org/articles/10.3389/fimmu.2021.746203/full
work_keys_str_mv AT petrospsfikakis bloodtranscriptomesofantisarscov2antibodypositivehealthyindividualswhoexperiencedasymptomaticversusclinicalinfection
AT petrospsfikakis bloodtranscriptomesofantisarscov2antibodypositivehealthyindividualswhoexperiencedasymptomaticversusclinicalinfection
AT kleiomariaverrou bloodtranscriptomesofantisarscov2antibodypositivehealthyindividualswhoexperiencedasymptomaticversusclinicalinfection
AT kleiomariaverrou bloodtranscriptomesofantisarscov2antibodypositivehealthyindividualswhoexperiencedasymptomaticversusclinicalinfection
AT giannisampatziadismichailidis bloodtranscriptomesofantisarscov2antibodypositivehealthyindividualswhoexperiencedasymptomaticversusclinicalinfection
AT ouraniatsitsilonis bloodtranscriptomesofantisarscov2antibodypositivehealthyindividualswhoexperiencedasymptomaticversusclinicalinfection
AT dimitriosparaskevis bloodtranscriptomesofantisarscov2antibodypositivehealthyindividualswhoexperiencedasymptomaticversusclinicalinfection
AT efstathioskastritis bloodtranscriptomesofantisarscov2antibodypositivehealthyindividualswhoexperiencedasymptomaticversusclinicalinfection
AT evilianidou bloodtranscriptomesofantisarscov2antibodypositivehealthyindividualswhoexperiencedasymptomaticversusclinicalinfection
AT paraskevimoutsatsou bloodtranscriptomesofantisarscov2antibodypositivehealthyindividualswhoexperiencedasymptomaticversusclinicalinfection
AT evangelosterpos bloodtranscriptomesofantisarscov2antibodypositivehealthyindividualswhoexperiencedasymptomaticversusclinicalinfection
AT ioannistrougakos bloodtranscriptomesofantisarscov2antibodypositivehealthyindividualswhoexperiencedasymptomaticversusclinicalinfection
AT vasilikichini bloodtranscriptomesofantisarscov2antibodypositivehealthyindividualswhoexperiencedasymptomaticversusclinicalinfection
AT menelaosmanoloukos bloodtranscriptomesofantisarscov2antibodypositivehealthyindividualswhoexperiencedasymptomaticversusclinicalinfection
AT panagiotismoulos bloodtranscriptomesofantisarscov2antibodypositivehealthyindividualswhoexperiencedasymptomaticversusclinicalinfection
AT panagiotismoulos bloodtranscriptomesofantisarscov2antibodypositivehealthyindividualswhoexperiencedasymptomaticversusclinicalinfection
AT georgiosapavlopoulos bloodtranscriptomesofantisarscov2antibodypositivehealthyindividualswhoexperiencedasymptomaticversusclinicalinfection
AT georgiosapavlopoulos bloodtranscriptomesofantisarscov2antibodypositivehealthyindividualswhoexperiencedasymptomaticversusclinicalinfection
AT georgekollias bloodtranscriptomesofantisarscov2antibodypositivehealthyindividualswhoexperiencedasymptomaticversusclinicalinfection
AT georgekollias bloodtranscriptomesofantisarscov2antibodypositivehealthyindividualswhoexperiencedasymptomaticversusclinicalinfection
AT georgekollias bloodtranscriptomesofantisarscov2antibodypositivehealthyindividualswhoexperiencedasymptomaticversusclinicalinfection
AT pantelishatzis bloodtranscriptomesofantisarscov2antibodypositivehealthyindividualswhoexperiencedasymptomaticversusclinicalinfection
AT pantelishatzis bloodtranscriptomesofantisarscov2antibodypositivehealthyindividualswhoexperiencedasymptomaticversusclinicalinfection
AT meletiosadimopoulos bloodtranscriptomesofantisarscov2antibodypositivehealthyindividualswhoexperiencedasymptomaticversusclinicalinfection
AT meletiosadimopoulos bloodtranscriptomesofantisarscov2antibodypositivehealthyindividualswhoexperiencedasymptomaticversusclinicalinfection
_version_ 1716843441053237248
spelling doaj-5544ae135ad64856b321e886966e1db22021-10-05T06:07:46ZengFrontiers Media S.A.Frontiers in Immunology1664-32242021-10-011210.3389/fimmu.2021.746203746203Blood Transcriptomes of Anti-SARS-CoV-2 Antibody-Positive Healthy Individuals Who Experienced Asymptomatic Versus Clinical InfectionPetros P. Sfikakis0Petros P. Sfikakis1Kleio-Maria Verrou2Kleio-Maria Verrou3Giannis Ampatziadis-Michailidis4Ourania Tsitsilonis5Dimitrios Paraskevis6Efstathios Kastritis7Evi Lianidou8Paraskevi Moutsatsou9Evangelos Terpos10Ioannis Trougakos11Vasiliki Chini12Menelaos Manoloukos13Panagiotis Moulos14Panagiotis Moulos15Georgios A. Pavlopoulos16Georgios A. Pavlopoulos17George Kollias18George Kollias19George Kollias20Pantelis Hatzis21Pantelis Hatzis22Meletios A. Dimopoulos23Meletios A. Dimopoulos24Center of New Biotechnologies & Precision Medicine, National and Kapodistrian University of Athens Medical School, Athens, GreeceJoint Rheumatology Program, National and Kapodistrian University of Athens Medical School, Athens, GreeceCenter of New Biotechnologies & Precision Medicine, National and Kapodistrian University of Athens Medical School, Athens, GreeceJoint Rheumatology Program, National and Kapodistrian University of Athens Medical School, Athens, GreeceCenter of New Biotechnologies & Precision Medicine, National and Kapodistrian University of Athens Medical School, Athens, GreeceDepartment of Biology, National and Kapodistrian University of Athens (NKUA), Athens, GreeceDepartment of Hygiene, Epidemiology and Medical Statistics, Medical School, National and Kapodistrian University of Athens, Athens, GreeceDepartment of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, GreeceDepartment of Chemistry, National and Kapodistrian University of Athens (NKUA), Athens, GreeceDepartment of Clinical Biochemistry, School of Medicine, University General Hospital Attikon, NKUA, Haidari, GreeceDepartment of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, GreeceDepartment of Cell Biology and Biophysics, Faculty of Biology, National and Kapodistrian University of Athens, Athens, GreeceCenter of New Biotechnologies & Precision Medicine, National and Kapodistrian University of Athens Medical School, Athens, GreeceCenter of New Biotechnologies & Precision Medicine, National and Kapodistrian University of Athens Medical School, Athens, GreeceCenter of New Biotechnologies & Precision Medicine, National and Kapodistrian University of Athens Medical School, Athens, GreeceInstitute for Fundamental Biomedical Research, Biomedical Sciences Research Center (BSRC) Alexander Fleming, Vari, GreeceCenter of New Biotechnologies & Precision Medicine, National and Kapodistrian University of Athens Medical School, Athens, GreeceInstitute for Fundamental Biomedical Research, Biomedical Sciences Research Center (BSRC) Alexander Fleming, Vari, GreeceCenter of New Biotechnologies & Precision Medicine, National and Kapodistrian University of Athens Medical School, Athens, GreeceJoint Rheumatology Program, National and Kapodistrian University of Athens Medical School, Athens, Greece0Institute for Bioinnovation, Biomedical Sciences Research Center (BSRC) Alexander Fleming, Vari, GreeceCenter of New Biotechnologies & Precision Medicine, National and Kapodistrian University of Athens Medical School, Athens, GreeceInstitute for Fundamental Biomedical Research, Biomedical Sciences Research Center (BSRC) Alexander Fleming, Vari, GreeceCenter of New Biotechnologies & Precision Medicine, National and Kapodistrian University of Athens Medical School, Athens, GreeceDepartment of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, GreeceThe reasons behind the clinical variability of SARS-CoV-2 infection, ranging from asymptomatic infection to lethal disease, are still unclear. We performed genome-wide transcriptional whole-blood RNA sequencing, bioinformatics analysis and PCR validation to test the hypothesis that immune response-related gene signatures reflecting baseline may differ between healthy individuals, with an equally robust antibody response, who experienced an entirely asymptomatic (n=17) versus clinical SARS-CoV-2 infection (n=15) in the past months (mean of 14 weeks). Among 12.789 protein-coding genes analysed, we identified six and nine genes with significantly decreased or increased expression, respectively, in those with prior asymptomatic infection relatively to those with clinical infection. All six genes with decreased expression (IFIT3, IFI44L, RSAD2, FOLR3, PI3, ALOX15), are involved in innate immune response while the first two are interferon-induced proteins. Among genes with increased expression six are involved in immune response (GZMH, CLEC1B, CLEC12A), viral mRNA translation (GCAT), energy metabolism (CACNA2D2) and oxidative stress response (ENC1). Notably, 8/15 differentially expressed genes are regulated by interferons. Our results suggest that subtle differences at baseline expression of innate immunity-related genes may be associated with an asymptomatic disease course in SARS-CoV-2 infection. Whether a certain gene signature predicts, or not, those who will develop a more efficient immune response upon exposure to SARS-CoV-2, with implications for prioritization for vaccination, warrant further study.https://www.frontiersin.org/articles/10.3389/fimmu.2021.746203/fullinnate immunityanti-SARS-CoV2 antibodyasympomaticRNAseqwhole-blood